Journal of Asthma最新文献

{"title":"Construction and validation of an immune gene-based model for diagnosis and risk prediction of severe asthma.","authors":"Yaqin Chen, Jiaye Xu, Liwei Liu, Han Li, Yufang Yang, Shen Cheng, Lan Li","doi":"10.1080/02770903.2024.2422410","DOIUrl":"10.1080/02770903.2024.2422410","url":null,"abstract":"<p><strong>Objective: </strong>Severe asthma (SA) is a serious disease with limited treatment options, which is closely linked to immune dysfunction. Therefore, immune-associated biomarkers may diagnose SA and offer therapeutic targets for SA.</p><p><strong>Methods: </strong>The gene expression profiles of SA patients and matched controls were from the National Center for Biotechnology Information database. Immune genes were downloaded from the ImmPort database. After screening for differentially expressed genes (DEGs) between SA patients and controls, and identifying gene modules highly associated with SA, immune-related DEGs were obtained. Then, protein-protein interaction analysis, Cytoscape software and receiver operating characteristic (ROC) curves were used to identify hub genes. Next, the relationship between hub genes and immune cells was explored, and single-sample gene set enrichment analysis (ssGSEA) was applied to conduct pathway enrichment analyses. Finally, the Least Absolute Shrinkage and Selection Operator (LASSO) combined with ROC analysis were used to confirm the diagnostic value of the hub genes.</p><p><strong>Results: </strong>Forty immune-related DEGs were obtained, and <i>RNASE3</i>, <i>CAMP</i> and <i>LTF</i> were determined as hub genes. The hub genes were closely associated with immune cells, and ssGSEA showed that lysosome was associated with high expressions of the hub genes, while primary immunodeficiency was related to low expressions of the hub genes. LASSO combined with ROC analysis confirmed the immune gene-based model (<i>RNASE3</i>, <i>CAMP</i>, <i>LTF</i>, and <i>CD79A</i>) could distinguish SA patients from healthy individuals with high sensitivity.</p><p><strong>Conclusions: </strong><i>RNASE3</i>, <i>CAMP</i>, <i>LTF</i>, and <i>CD79A</i> could act as diagnostic markers for SA, providing a theoretical basis for developing diagnostic targets for SA.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"577-590"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impaired respiratory functions in children with cat sensitization in the early ages of childhood.","authors":"Simge Atar Bese, Adnan Mercan, Duygu Erge, Pınar Uysal","doi":"10.1080/02770903.2024.2428281","DOIUrl":"10.1080/02770903.2024.2428281","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the respiratory functions in children with cat sensitization accompanying allergic respiratory diseases and to compare these with those of healthy controls, as well as within themselves by classifying according to their diseases, domestic cat exposure, and age groups.</p><p><strong>Methods: </strong>This prospective case-control study included 130 children aged 3-17 years with cat sensitization (CS group) accompanying respiratory allergic diseases and 70 age- and sex-matched healthy controls (HC group). The cases' demographic parameters were recorded, and respiratory functions were analyzed using IOS and spirometry.</p><p><strong>Results: </strong>At IOS evaluation, zR5, R5-20, Fres, and AX values were higher in children in the CS group compared to the HC group (<i>p</i> = 0.029, <i>p</i> = 0.008, <i>p</i> = 0.001, and <i>p</i> < 0.001, respectively), while zX5 and zX20 values were lower (<i>p</i> = 0.001 and <i>p</i> < 0.001). R5-20 and AX were higher in asthma compared to allergic rhinitis (<i>p</i> = 0.008, <i>p</i> = 0.015), but were insignificant compared to asthma and allergic rhinitis coexistent group (<i>p</i> > 0.05). R5-20, Fres, and AX were higher, and zX20 was lower in the preschool age group (<i>p</i> < 0.001). No correlation was found between zFEV1, zFVC, zFEV1/FVC, zFEF25-75, and zR5 values in the CS group (<i>p</i> > 0.05).</p><p><strong>Conclusions: </strong>Pulmonary resistance was higher and reactance was lower in the entire and peripheral airways in children with cat sensitization accompanying respiratory allergic diseases compared to the healthy controls. Peripheral airway resistance and reactance were more impaired in the asthma group compared to allergic rhinitis. However, peripheral airway resistance and main airway reactance were more impaired in the preschool age group than in the older ones.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"637-646"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory analysis of the economically justifiable price of tezepelumab for asthma severe in Colombia.","authors":"Jefferson Antonio Buendía, Andres Felipe Zuluaga","doi":"10.1080/02770903.2024.2438093","DOIUrl":"10.1080/02770903.2024.2438093","url":null,"abstract":"<p><strong>Introduction: </strong>Asthma severe imposes important economic burden on health systems, especially with the incorporation of new drugs. Recently, tezepelumab has been approved to prevent exacerbations in patients. This study explores the economically justifiable price of tezepelumab for preventing exacerbations in patients with severe asthma.</p><p><strong>Materials and methods: </strong>A static model was developed using the decision tree microsimulation to estimate the quality-adjusted life years of two interventions: a single intramuscular dose of tezepelumab versus not applying tezepelumab. This analysis was made during a time horizon of 50 year and from a third-payer perspective.</p><p><strong>Results: </strong>Based on thresholds of U$4828, U$ 5128, and U$19 992 per QALY evaluated in this study, we established economically justifiable drug acquisition prices of U$ 795, U$ 835, and U$ 3384 per dose of Tezepelumab. Tezepelumab not was cost-effective using a WTP of U$4828 and U$ 5128. It only was cost effective at WTP of U$19 992 per QALY.</p><p><strong>Conclusion: </strong>The economically justifiable cost for tezepelumab in Colombia is between U$795 to U$3384 per dose, depending on the WTP used to decide its implementation. This result should encourage more studies in the region that optimize decision-making processes when incorporating this drug into the health plans of each country.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"684-693"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding how sleep disorders are managed in people with asthma: A scoping review of the literature.","authors":"Emma Yau, Janet M Y Cheung, Bandana Saini, Stephen Hughes","doi":"10.1080/02770903.2025.2487986","DOIUrl":"https://doi.org/10.1080/02770903.2025.2487986","url":null,"abstract":"<p><strong>Objective: </strong>People with asthma may experience sleep disturbances due to uncontrolled asthma symptoms and/or co-occurring sleep disorders. Asthma shares pathophysiological pathways with sleep disorders including insomnia and obstructive sleep apnea and the interrelationship between asthma and sleep disorders is bi-directional. Insufficient sleep in general and in people with asthma leads to worsened mental and physical health. How this is managed in people with asthma is less known.</p><p><strong>Data sources: </strong>This scoping review examines current literature around sleep health management employed by people with asthma and their care providers. Peer reviewed journal articles on sleep health interventions/management in adults with comorbid asthma were searched for in 4 databases, across 10 years, in a search strategy developed with medical librarians.</p><p><strong>Study selection: </strong>The search led to the inclusion of 13 studies that met the review criteria, which reported sleep management interventions tested in people with sleep disorders comorbid with asthma.</p><p><strong>Results: </strong>For people with obstructive sleep apnea and asthma, continuous positive pressure devices, oral appliances and bariatric surgery improved sleep and asthma outcomes. Improvements in other sleep disorders and asthma were shown with behavioral interventions and digital interventions including fitness tracker use.</p><p><strong>Conclusion: </strong>The limited studies retrievable on this topic suggest management of sleep disorders in people with asthma is an under-researched area. Future research directed at how and when to assess sleep management in people with asthma will better inform specific guidelines and achieve improved sleep health in this population.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-24"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>In silico</i> B-cell epitope prediction and molecular docking of <i>Aspergillus</i> allergens targeting improved ABPA diagnosis.","authors":"Diksha Agrawal, Monika Sharma, Ruchi Sachdeva, Pragya Priyadarshini, Anu Priya Minhas","doi":"10.1080/02770903.2024.2419452","DOIUrl":"10.1080/02770903.2024.2419452","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to <i>in silico</i> predict <i>Aspergillus fumigatus</i> specific B-cell epitopes with a focus on enhancing Allergic Bronchopulmonary Aspergillosis (ABPA) diagnostic precision by using and to validate using molecular docking of <i>Aspergillus fumigatus</i> specific B-cell epitopes, aiming to overcome current serological and clinical method limitations and to support specific therapies and preventive strategies for better ABPA management.</p><p><strong>Methods: </strong>The sequences of Asp f1, Asp f2, Asp f3, and Asp f4 from NCBI were analyzed using IEDB-AR for B-cell epitope prediction. Structural modeling and molecular docking analysis were conducted using MODELER and HADDOCK, respectively, with visualization via PyMOL and PDBe PISA.</p><p><strong>Results: </strong>For Asp f1, two IgE-specific (40-47) and four IgG-specific (33-76, 125-148) B-cell epitopes were predicted. Asp f3 had one IgG-specific epitope (47-73), and Asp f4 had two IgG-specific epitopes (52-133) with no IgE epitopes. Asp f2 had eight IgE-specific epitopes (56-63, 93-99, 136-146, 153-160, 185-194, 200-206, 229-239) with IgPred scores above 0.931 and no IgG-specific epitopes. Molecular docking with HADDOCK Z-scores showed strong interactions between IgE and Asp f1 and Asp f2 epitopes. PyMOL and PISA-EBI identified key residues: LYS43 in Asp f1 forms a salt bridge with the IgE heavy chain. In Asp f2, out of nineteen identified residues, six residues (LYS 94, ARG 153, ASP 200, ASP 204, ASP 207 and GLU 233) were confirmed as part of the predicted IgE epitopes, exhibiting significant interactions with IgE, in agreement with both PyMOL and PISA analysis.</p><p><strong>Conclusion: </strong>This study aimed to enhance ABPA diagnostics by identifying key B-cell epitopes of <i>Aspergillus fumigatus</i> through <i>in silico</i> prediction and molecular docking, a way to support personalized therapies and preventive strategies in future.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"554-565"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sevoflurane-induction via the Flow-i ventilator in the pediatric intensive care unit for the treatment of status asthmaticus: a case report and literature review.","authors":"Ahmani DoDoo, Melissa Cregan, Kailey A Remien, Ambrish Patel","doi":"10.1080/02770903.2025.2482995","DOIUrl":"https://doi.org/10.1080/02770903.2025.2482995","url":null,"abstract":"<p><strong>Introduction: </strong>Status asthmaticus is a severe asthma exacerbation commonly associated with hypercarbia, hypoxia, and respiratory acidosis that can be unresponsive to conventional therapies. Non-invasive positive pressure ventilation is utilized as the first modality of respiratory support. Inhaled anesthetic agents are non-standard treatment options which can be considered for their bronchodilator properties once the patient is intubated.</p><p><strong>Case report: </strong>We present a 14-year-old adolescent with a history of severe persistent asthma who was admitted to the pediatric intensive care unit (PICU) in status asthmaticus. The patient required intubation, was induced with sevoflurane, and mechanically ventilated with the Flow-i ventilator.</p><p><strong>Discussion: </strong>Status asthmaticus is described as severe asthma that is refractory to repeated administration of beta-agonists, while near-fatal asthma is described as exacerbations requiring intubation and mechanical ventilation. When mechanical ventilation and conventional therapies are inadequate, inhalational anesthetics and extracorporeal membrane oxygenation (ECMO) are considered. This article examines the use of sevoflurane as a treatment modality for pediatric patients with status asthmaticus highlighting the therapeutic approach and outcome.</p><p><strong>Conclusion: </strong>The use of inhaled anesthetic gases and advanced anesthesia machines can diversify and enhance treatment for patients with refractory status asthmaticus. With continuous monitoring of hemodynamics, anesthesia machines may be an integral therapeutic option for treating refractory status asthmaticus within the PICU without the need for extracorporeal life support.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-8"},"PeriodicalIF":1.7,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics associated with activities of daily living (ADL), instrumental activities of daily living (IADL), functional, or other activity limitation among United States adults with asthma.","authors":"David R Axon","doi":"10.1080/02770903.2025.2482993","DOIUrl":"10.1080/02770903.2025.2482993","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to explore the characteristics associated with having a limitation, which included any activities of daily living (ADL), instrumental activities of daily living (IADL), functional, or other activity limitations, among adults with asthma in the United States (US).</p><p><strong>Methods: </strong>This cross-sectional study included US adults (≥18 years) with asthma in the 2021 Medical Expenditure Panel Survey. A multivariable logistic regression model assessed the association between the following characteristics and the dependent variable (having a limitation, which included ADL, IADL, functional, or other activity limitation): age, sex, race, ethnicity, education, employment, income, marriage, exercise, smoking, pain, overall health, and mental health.</p><p><strong>Results: </strong>The sample included 2325 (limitation <i>n</i> = 940, no limitation <i>n</i> = 1385) US adults with asthma, which represented an estimated weighted population of 37 210 236 (limitation <i>n</i> = 11 104 087, no limitation <i>n</i> = 26 106 149). In this analysis, characteristics associated with having a limitation (versus no limitation) included: age ≥65 versus 18-39 years (odds ratio (OR)=6.6, 95% confidence interval (CI)=3.8-11.4), age 40-64 versus 18-39 years (OR = 2.4, 95% CI = 1.5-3.9), unemployed versus employed (OR = 2.6, 95% CI = 1.7-4.0), low versus middle/high income (OR = 1.5, 95% CI = 1.0-2.2), not married versus married (OR = 1.8, 95% CI = 1.2-2.7), smoker versus nonsmoker (OR = 3.0, 95% CI = 1.7-5.3), quite a bit/extreme versus little/moderate pain (OR = 2.8, 95% CI = 1.8-4.3), fair/poor versus good overall health (OR = 3.3, 95% CI = 2.0-5.3), and fair/poor versus excellent/very good overall health (OR = 6.3, 95% CI = 3.5-11.4).</p><p><strong>Conclusions: </strong>In conclusion, these findings offer some insight into having a limitation among US adults with asthma, although a future prospective study is needed to establish evidence of causality.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-8"},"PeriodicalIF":1.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overestimation of asthma control and misperception of the place of short-acting β2-agonists in asthma management: a prospective, real-world study among physicians in Poland.","authors":"Radosław Gawlik, Grażyna Bochenek, Dorota Brzostek, Adam Stasiulewicz, Wojciech Barg, Grzegorz Brożek, Piotr Dąbrowiecki, Andrzej Dąbrowski, Rafał Dobek, Aleksandra Kucharczyk, Maciej Kupczyk, Izabela Kupryś-Lipińska, Agnieszka Mastalerz-Migas, Marek L Kowalski","doi":"10.1080/02770903.2025.2472354","DOIUrl":"10.1080/02770903.2025.2472354","url":null,"abstract":"<p><strong>Objective: </strong>Overestimation of asthma control remains a substantial healthcare issue. Overuse of short-acting β2-agonists (SABA), one of the aspects of poor asthma control, was highlighted by the SABINA project as a worldwide problem. The objective of this study was to investigate the asthma control assessment and the perception of the SABA role in asthma therapy among Polish allergists, pulmonologists, and general practitioners.</p><p><strong>Methods: </strong>The study included 253 Polish allergists, pulmonologists, and general practitioners.Data were gathered using a qualitative questionnaire regarding physicians' practices and opinions and a quantitative one - an extended Patient Diary Study with information about asthma control of 2482 patients. The answers were compared with Global Initiative for Asthma (GINA) criteria.</p><p><strong>Results: </strong>Physicians assessed asthma control at 69.1-89.8% of visits, based mainly on symptoms (96% of physicians), followed by drug consumption (65-80%) and diagnostic tests (40-79%). According to GINA standards, 32.4-43.3% of patients had controlled and 27.3-33.9% uncontrolled asthma. Physicians in all specialties overestimated the percentage of patients with controlled asthma and the level of control was overestimated for 68-84% of uncontrolled patients. Over 90% of physicians agreed or strongly agreed that SABA consumption is an important indicator of asthma control; 58-81% agreed that SABA consumption should be monitored as an indicator of asthma control; 74-90% stated that SABA were rescue medications that patients must have; 59-68% agreed that SABA consumption should be reduced.</p><p><strong>Conclusions: </strong>The results of this study show a strong need for physicians' education regarding objective asthma control assessment and the role of SABA in asthma therapy.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-9"},"PeriodicalIF":1.7,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous thromboembolism associated with severe dyspnea and asthma in 21,205 adults from the Danish population.","authors":"Kristin Felicia Nilausen, Delia-Ioana Radutiu, Eskild Morten Landt, Suzan Al-Shuweli, Børge G Nordestgaard, Uffe Bødtger, Morten Salling Olesen, Christina Ellervik, Morten Dahl","doi":"10.1080/02770903.2025.2478512","DOIUrl":"10.1080/02770903.2025.2478512","url":null,"abstract":"<p><strong>Background: </strong>Long-term consequences after a pulmonary embolism include lung function deficits, dyspnea, and chronic thromboembolic pulmonary hypertension. Recent studies suggest patients who experience pulmonary embolism may also be at increased risk of asthma.</p><p><strong>Methods: </strong>We tested the hypothesis that individuals with pulmonary embolism or deep vein thrombosis (venous thromboembolism) have lower lung function, or higher risks of dyspnea and asthma using data from 21,205 random adults from the Danish General Suburban Population Study.</p><p><strong>Results: </strong>Prevalences of pulmonary embolism, deep vein thrombosis, and venous thromboembolism were 0.60%, 1.7%, and 1.9%, respectively. Individuals with pulmonary embolism or deep vein thrombosis had FEV₁% predicted of 86% and 89% compared with 95% in individuals without venous thromboembolism (<i>t</i>-test: <i>p</i> < .001). Corresponding values for FVC% predicted were 92% and 94% versus 99% (<i>p</i> < .001). Individuals with versus without venous thromboembolism had adjusted odds ratios for light, moderate, and severe dyspnea of 1.6 (95% CI: 1.1-2.2), 1.8 (1.2-2.6), and 2.6 (1.8-3.8), respectively. Individuals with versus without venous thromboembolism had adjusted odds ratios for asthma and use of asthma medication of 1.6 (1.2-2.2) and 1.9 (1.4-2.6), respectively. The adjusted odds ratio for asthma in individuals with versus without venous thromboembolism was increased among individuals who received no treatment with anticoagulants (2.0, 1.4-3.0) compared to those who received treatment (1.0, 0.6-1.6) (<i>p</i> for interaction = .02).</p><p><strong>Conclusions: </strong>Individuals with venous thromboembolism have lower lung function, 2.6-fold higher risk of severe dyspnea, and 1.6-fold higher risk of asthma in the Danish population.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-7"},"PeriodicalIF":1.7,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mediation analysis of gut microbiota and plasma metabolites in asthma pathogenesis using Mendelian randomization.","authors":"XuWen Zheng, JinNan Yin, Liang Zhao, YongJun Qian, Jin Xu","doi":"10.1080/02770903.2025.2478504","DOIUrl":"10.1080/02770903.2025.2478504","url":null,"abstract":"<p><strong>Objective: </strong>Asthma is a prevalent chronic respiratory condition with multifactorial pathogenesis. Emerging evidence suggests that gut microbiota and their metabolites influence asthma risk. This study explores the mediation effects of plasma metabolites between gut microbiota and asthma using Mendelian randomization (MR) analysis.</p><p><strong>Methods: </strong>Publicly available genome-wide association study (GWAS) data were analyzed, comprising 5,959 individuals for gut microbiota, 8,299 for plasma metabolites, and 543,586 (86,923 cases and 456,663 controls) for asthma outcomes. MR analyses were conducted to evaluate causal relationships between gut microbiota, plasma metabolites, and asthma. Mediation effects were assessed using the product of coefficients approach, and statistical significance was determined with Bonferroni correction.</p><p><strong>Results: </strong>The MR analysis identified 24 gut microbiomes and 88 plasma metabolites with suggestive associations with asthma. Notably, mediation analysis revealed that the phylum <i>Cyanobacteria</i> reduced asthma risk <i>via</i> the alpha-tocopherol to glycerol ratio (mediated proportion: 37.48%), while the species <i>UBA2922 sp900313925</i> and the order <i>Parachlamydiales</i> increased risk through arachidonate to linoleate (14.62%) and hypotaurine to taurine (29.36%) ratios, respectively.</p><p><strong>Conclusion: </strong>This study underscores the significant role of the gut microbiota-lung axis in asthma pathogenesis. By identifying specific gut microbiota and metabolite pathways, the findings pave the way for innovative biomarkers and therapeutic strategies targeting gut microbiota and its metabolites to manage and prevent asthma.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-13"},"PeriodicalIF":1.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}